ACRS Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Aclaris Therapeutics Inc

Watchlist Manager

Watchlist

Price: 5.2 USD -2.26% Market Closed

Market Cap: $726.2m

	Aclaris Therapeutics Inc NASDAQ:ACRS	US
N	Nissan Chemical Corp DUS:NSC	JP
	LiveOne Inc F:351	US

Profitability Summary

Aclaris Therapeutics Inc's profitability score is 13/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

10%

Sustainable 3Y Average Gross Margin

26%

Declining Gross Margin

58% > 10%

Negative Operating Margin

-962%

Negative 3Y Average Operating Margin

-576%

Declining Operating Margin

-336% > -962%

Negative Net Margin

-833%

Negative 3Y Average Net Margin

-563%

Declining Net Margin

-338% > -833%

Negative Free Cash Flow Margin

-625%

Negative 3Y Average Free Cash Flow Margin

-344%

Declining Free Cash Flow Margin

-241% > -625%

Negative ROE

-48%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-156%

ROIC is Increasing

-163% > -98%

View All

Hide

Collapse

13 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.